Evaluating Endopredict® test in early HR+/HER2- breast cancer
Part of Cancer, Skin clinical trials.
This study looks at how well the Endopredict® genomic test helps doctors decide whether chemotherapy should be added to hormone therapy for people with early-stage, HR+/HER2- breast cancer. It is for those whose standard criteria are not enough to make a clear recommendation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage breast cancer that is hormone receptor-positive (HR+) and HER2-negative.
- After your breast surgery, standard clinical information wasn't enough to decide if chemotherapy would help.
- You have not had the Endopredict® test, or if you did, the results were not used to guide your treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether ovarian function suppression (a treatment that lowers hormone production from the ovaries) helps women with hormone-receptor positive, HER2-negative breast cancer that has spread to lymph nodes, but who have a low-risk result on a genomic test. It may help reduce breast cancer recurrence while avoiding more intensive treatment for those who are lower risk.
This study looks at a blood test (DiviTum TKa) to see how well it measures treatment response in people with hormone receptor-positive (HR+) breast cancer that has spread. The test may help doctors know if a treatment is working.
This study looks at how genomic tests (which analyze your tumor's genes) are used in routine care for early-stage breast cancer that is hormone-sensitive. It may help doctors understand who really needs chemotherapy in addition to hormone therapy.
This trial tests whether we can predict how well hormone therapy works before surgery for early-stage breast cancer. It may help women with estrogen receptor-positive, HER2-negative or HER2-low breast cancer avoid or tailor treatments.
This trial uses a genomic test called Prosigna to help decide whether young women with hormone-sensitive breast cancer need chemotherapy after surgery. It aims to avoid unnecessary chemotherapy in those who can safely skip it.
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
Hear when a new Breast Cancer Survivors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.